tbuckley/cabot-search huggingface dataset:
535P Long term quality of life after chemotherapy among nonepithelial ovarian cancer survivors: The case-control vivrovaire rare tumours study
Authors: F. Joly Lobbedez, I.L. Ray-Coquard, S. Lefevre Arbogast, J-M. Grellard, B. Clarisse, A. Floquet, F. Selle, D. Berton-Rigaud, S. Frank, T. De La Motte Rouge, E. Kalbacher, M. Provansal Gross, None A. lortholary, H. Orfeuvre, J. Alexandre, P. Augereau, J.E. Kurtz, C. Nadeau, P. Pautier, F. Gernier
Journal: Annals of Oncology (2022)
361P Tucatinib plus trastuzumab in patients (Pts) with HER2-positive metastatic colorectal cancer (mCRC): Patient-reported outcomes (PROs) from ph II study MOUNTAINEER
Authors: C. Wu, J.H. Strickler, A. Cercek, S. Siena, T. André, K. Ng, E. Van Cutsem, A.S. Paulson, J. Hubbard, A. Coveler, C. Fountzilas, A. Kardosh, P.M. Kasi, H.J. Lenz, K.K. Ciombor, M.E. Elez Fernandez, L-I. Hsu, M. Stecher, K. Zhao, T. Bekaii-Saab
Journal: Annals of Oncology (2022)
826P Encorafenib and binimetinib followed by radiotherapy for patients with symptomatic BRAF mutated melanoma brain metastases: GEM1802/E-BRAIN clinical trial
Authors: I. Marquez-Rodas, A.M. Arance Fernandez, M.A. Berciano Guerrero, A. Garcia Castano, M.D.C. Alamo De La Gala, M. Gonzalez Cao, P. Sanchez Mauriño, R.P. Diaz Beveridge, I. Valduvieco, R. Delgado, P.J. Prada, E. Puertas, J.L. Romero, A. Conde, A. Alvarez, A. Berrocal
Journal: Annals of Oncology (2022)
105P Pan-tumor survey of ROS1 fusions detected by next-generation RNA sequencing
Authors: S. Zhang, M. Nagasaka, Y. Baca, J. Xiu, None J.J. Nieva, A. VanderWalde, J.J. Swensen, D. Spetzler, W.M. Korn, S.V. Liu, S-H.I. Ou
Journal: Annals of Oncology (2022)
920P Blind validation of MSIntuit, an AI-based pre-screening tool for MSI detection from colorectal cancer H&amp;E slides
Authors: M. Svrcek, C. Saillard, R. Dubois, N. Loiseau, P. Mespoulhe, F. Brulport, J. Guillon, M. Auffret, M. Sefta, A. Kamoun, P. Courtiol, S. Rossat, F. Renaud, A. Fouillet, G. Wainrib
Journal: Annals of Oncology (2022)
766P Levels of serum EGF concentration as biomarker of response of CIMAvax-EFG vaccine: Survival evaluation of advanced NSCLC patients treated in primary health care scenario
Authors: R.A. Otiz Carrodeguas, G. Lorenzo Monteagudo, P.P. Guerra, L. Sanchez, L. Cárdenas, I. Álvarez, E.E. Salomón, M. Díaz, Y. Menéndez, L. Lobaina, J.C. Columbié, K. Camacho, M. Corella, N. Fardales, J. Parra, C. Viada, D. Saavedra, O. Santos, T. Crombet Ramos
Journal: Annals of Oncology (2022)
451O Preliminary evidence of clinical activity from phase I and Ib trials of the CLK/DYRK inhibitor cirtuvivint (CIRT) in subjects with advanced solid tumors
Authors: A. Scott, J.A. Call, S. Chandana, E. Borazanci, G.S. Falchook, R. Bordoni, S. Richey, A. Starodub, V. Chung, N.J. Lakhani, E. Lam, K. Schaffer, J.S. Wang, G. Shapiro, J.C. Sachdev, D. Beaupre, A.W. Tolcher
Journal: Annals of Oncology (2022)
794P Efficacy and tolerability of neoadjuvant treatment with T-VEC in difficult to resect primary basal cell carcinoma: A phase II clinical trial (NeoBCC)
Authors: J.M. Ressler, A. Kusienicka, R. Silmbrod, T. Silly, V. Bachmayr, M. Plaschka, L.E. Shaw, N. Zila, A. Stepan, P. Tschandl, J. Tittes, F. Roka, W. Haslik, F. Koenig, R. Kunstfeld, P. Petzelbauer, F. Halbritter, W. Weninger, M. Farlik, C. Hoeller
Journal: Annals of Oncology (2022)
187P Routine care of early breast cancer (stage I-III) in Germany: Data of the prospective, intersectoral research platform OPAL
Authors: A. Welt, M-O. Zahn, A. Wöckel, E. Stickeler, M. Thoma, A. Nusch, S. Fuxius, L. Müller, D. Reschke, M. Chiabudini, L. Hillebrand, L. Kruggel, M. Jänicke, N.W. Marschner, M. Thill, N. Harbeck, T. Decker
Journal: Annals of Oncology (2022)
485P Correlation of clinical, genomic and hematological parameters with ATR inhibitor (ATRi) outcomes in phase I/II clinical trials
Authors: N.Y.L. Ngoi, H. Lin, E.E. Ileana Dumbrava, S. Fu, D. Karp, A. Naing, S. Pant, J. Rodon, S. Piha-Paul, V. Subbiah, A.M. Tsimberidou, E. Campbell, S. Urrutia, D.S. Hong, F. Meric-Bernstam, Y. Yuan, T.A. Yap
Journal: Annals of Oncology (2022)
246P Nanosomal paclitaxel lipid suspension demonstrates better tumor response and safety versus conventional paclitaxel in patients with metastatic breast cancer
Authors: S. Chiradoni Thungappa, R. Taran, J.K. Singh, S.P. Shrivastav, N.K. Vithalani, K.K. Mukherjee, R. Nagarkar, T.M. Maksud, A. Mehta, K. Srinivasan, M. Vikranth, S.R. Sonawane, A. Ahmad, S. Sheikh, S.M. Ali, M. Paithankar, A. Rajani, D. Bunger, M.A. Khan, I. Ahmad
Journal: Annals of Oncology (2022)
489P Analysis of 3-dimensional volumetric distribution and dispersion of the radioenhancer NBTXR3 in various solid malignancies
Authors: T. de Baere, C. Shen, A. Ducassou, S. Bonvalot, E. Chajon, L. Farber, O.I. Vivar, P. Tyan, E.J. Koay, S.H. Lin, Z. Liao, A.P. Dicker, C. Hoffmann, C. Le Tourneau
Journal: Annals of Oncology (2022)
234P CDK 4/6 inhibitors (CDK4/6i) for metastatic breast cancer (mBC): The Likelihood of being Helped or Harmed (LHH) as a patient-centred tool to assess clinical impact and safety
Authors: L. Mastrantoni, A. Orlandi, A. Palazzo, G. Garufi, A. Fabi, G. Daniele, D. Giannarelli, G. Tortora, E. Bria
Journal: Annals of Oncology (2022)
484P CHARIOT trial (cohort A2): A phase I dose-escalation study combining the ATR inhibitor berzosertib with cisplatin and capecitabine
Authors: S. El Badri, S. Lord, R. Harman, D. McIntosh, S. Mukherjee, A. Ooms, M. Parkes, G. Radhakrishna, P.H. Shaw, M.A. Hawkins
Journal: Annals of Oncology (2022)
341P Trop2 and Nectin4 immunohistochemical expression in metastatic colorectal cancer: An exploratory analysis of the TRIBE2 study
Authors: V. Conca, M.M. Germani, R. Moretto, M. Giordano, F. Bergamo, M. Prisciandaro, C. Antoniotti, C. Ugolini, D. Santini, S. Cupini, A. Boccaccino, G. Barsotti, F. Pagani, C. Niccoli, A. Zaniboni, A. Passardi, E. Tamburini, T.P. Latiano, G. Fontanini, C. Cremolini
Journal: Annals of Oncology (2022)
339P Molecular subtyping for chemotherapy response prediction in early stage colon cancer
Authors: S. van de Weerd, A. Torang, M. Smit, I. van den Berg, J. Roelands, W. Mesker, D. Bedognetti, P. Kuppen, H. Putter, R.A.E.M. Tollenaar, W.R.L. Hendrickx, C. Jimenez, G. Vink, M. Koopman, J. Roodhart, J. Ijzermans, H. van Krieken, J-P. Medema
Journal: Annals of Oncology (2022)
689P Effects of durvalumab-metformin on head and neck squamous cell carcinoma (HNSCC) as revealed by digital spatial profiling (DSP)
Authors: J. Riordan, A. Linnenbach, A. Alnemri, R. Philips, S. Awosanya, S. Sussman, A. Luginbuhl, D. Cognetti, L. Harshyne, M. Mahoney, A. South, D. Whitaker-Menezes, M. Tuluc, A. Argiris, U. Martinez-Outschoorn, J.M. Johnson, J.M. Curry
Journal: Annals of Oncology (2022)
816P Investigating surrogate endpoints (SE) for overall survival (OS) in first-line (1L) advanced melanoma: A pooled-analysis of immune checkpoint inhibitor (ICI) trials
Authors: J. Larkin, P. Squifflet, E.D. Saad, P. Mohr, M. Kurt, A. Moshyk, M. Hamilton, S. Kotapati, M.E. Buyse
Journal: Annals of Oncology (2022)
663P Camrelizumab plus apatinib in patients with recurrent or metastatic nasopharyngeal carcinoma failing first-line therapy: An open-label, single-arm, phase II study
Authors: X. Ding, W. Zhang, R. You, X. Zou, Z. Wang, Y-F. Ouyang, Y-L. Liu, L. Peng, L. You-Ping, C-Y. Duan, Q. Yang, C. Lin, X. Yulong, S-Y. Chen, C-M. Gu, P.Y. Huang, Y. Hua, M. Chen
Journal: Annals of Oncology (2022)
818P Phase II confirmatory study of cemiplimab (350mg IV Q3W) in patients with locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): Study 1540 Group 6
Authors: B.G.M. Hughes, J.J. Grob, S.E. Bowyer, F.L. Day, R. Ladwa, B. Stein, E. Muñoz Couselo, N. Basset-Seguin, A. Guminski, L. Mortier, A. Hauschild, M.R. Migden, C. Schmults, S-Y. Yoo, J. Booth, F. Seebach, I. Lowy, M.G. Fury, D. Rischin
Journal: Annals of Oncology (2022)
916P Deep learning-based multimodal ensemble algorithm for multi-cancer detection and classification using cf-WGS
Authors: J. Lee, T-R. Lee, G. Kim, J.M. Ahn, S.R. Park, K-B. Song, E. Jun, D. Oh, J-W. Lee, Y.S. Park, G-W. Song, J-S. Byeon, B.H. Kim, J. Lee, D. Kim, C-S. Ki, E. Cho, J.K. Choi
Journal: Annals of Oncology (2022)
625MO Combination of mitoxantrone hydrochloride liposome with pegaspargase in patients with extranodal NK/T-cell lymphoma: A phase I/II clinical trial
Authors: Y. Huang, T. Wu, Y. Hu, Y. Li, J. Ma, Y. Guo, H. Zhou, R. Yang, Y. Gong, Q.Y. Zhang, L.E. Lin, R. Zhou, Y. Liu, Z. Pan, J. Xue, D. Wang
Journal: Annals of Oncology (2022)
290P Potential enrichment strategies for next-generation sequencing (NGS) in primary brain cancers (pBCs) in a clinical series according to ESMO scale for clinical actionability of molecular targets (ESCAT)
Authors: O. Mirallas, D.E. López Valbuena, J. Yaringaño, B. Martin Cullell, D.G. Illescas, S. Aguilar Izquierdo, E. Martínez-Sáez, A. Pedrola, A. Vivancos, N. Saoudi Gonzalez, F.J. Ros Montana, M. Gonzalez Rodriguez, R. Dienstmann, J. Mateo, J. Tabernero, E. Garralda, J. Carles Galceran, M. Vieito Villar
Journal: Annals of Oncology (2022)
128P Histopathology (HP) biomarkers confirm leukocyte interleukin injection (LI) treatment (Tx) outcome in naïve locally advanced primary head &amp; neck squamous cell carcinoma (SCCHN) the IT-MATTERS study
Authors: J. Timar, E. Talor, P. Lavin, A. Ladanyi, I. Kenessey, A. Kiss, D. Markovic, J. Cipriano
Journal: Annals of Oncology (2022)
83P Patterns of trophoblast cell surface antigen 2 (TROP2) and epithelial cell adhesion molecule (EPCAM) expression in human tumors: A tissue microarray study on 14,766 tumors
Authors: D. Dum, C. Hube-Magg, R. Simon, E. Bady, T. Mandelkow, N.C. Blessin, M. Lennartz, G. Sauter, S. Minner, A.M. Luebke
Journal: Annals of Oncology (2022)
438TiP MOUNTAINEER-03: Phase III study of tucatinib, trastuzumab, and mFOLFOX6 as first-line treatment in HER2+ metastatic colorectal cancer (trial in progress)
Authors: T. André, T. Bekaii-Saab, J. Tabernero, S. Siena, T. Yoshino, K.G. Norwood, D.E. Adelberg, J. Ward, S. Yang, J.H. Strickler, E. Van Cutsem
Journal: Annals of Oncology (2022)
658MO Pembrolizumab (pembro) vs standard-of-care (SOC) in previously treated recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): 6-year follow-up of KEYNOTE-040
Authors: D. Soulieres, K.J. Harrington, C. Le Tourneau, J.D. Silva, L.F. Licitra, M-J. Ahn, A. Soria, J-P. Machiels, N. Mach, R. Mehra, B. Burtness, J. Lin, N. Lerman, B. Gumuscu, E.E.W. Cohen
Journal: Annals of Oncology (2022)
265P Phase II study of DHP107 oral paclitaxel compared to IV paclitaxel in patients with HER2-negative recurrent or metastatic breast cancer (MBC): Opera (NCT03326102)
Authors: H.S. Rugo, T.J. Pluard, P. Sharma, M. Melisko, G. Al-Jazayrly, Y. Ji, N. Vidula, J.A. Ellerton, M. Smakal, M. Zimovjanova, D. Weng, K.E. Yoon, H.J. Cho
Journal: Annals of Oncology (2022)
259P Efficacy of eribulin mesylate in HER2-low metastatic breast cancer (MBC): Results from three phase III studies
Authors: P.A. Kaufman, C.J. Twelves, A.H. Awada, S-A. Im, L. Vahdat, B. Xu, P. Yuan, W. Hauck, R. Xie, B. Lalayan, J. Cortés
Journal: Annals of Oncology (2022)
319MO Real-world monitoring of circulating tumor DNA reliably predicts cancer recurrence in patients with resected stages I-III colorectal cancer
Authors: S.A. Cohen, P.M. Kasi, V.N. Aushev, D.L. Hanna, G.P. Botta, S. Sharif, G. Laliotis, S. Sharma, V. Sharma, A. Alqahtani, S.R. Chandana, None S. Kang, S. Chakrabarti, B.G. Somer, A. Kasi, F. Dayyani, M. Malla, A. Jurdi, A. Aleshin, S. Kopetz
Journal: Annals of Oncology (2022)
992P Updated analyses from the CROWN study of first-line lorlatinib vs crizotinib in Asian patients with ALK-positive non-small cell lung cancer (NSCLC)
Authors: Z. Qing, H.R. Kim, R.A. Soo, C.H. Chiu, H. Hayashi, S-W. Kim, S. Teraoka, D-W. Kim, H. Zhan, H. Zhao, H. Li, T.S.K. Mok, Y-L. Wu
Journal: Annals of Oncology (2022)
211MO Giredestrant (GDC-9545) vs physician choice of endocrine monotherapy (PCET) in patients (pts) with ER+, HER2– locally advanced/metastatic breast cancer (LA/mBC): Primary analysis of the phase II, randomised, open-label acelERA BC study
Authors: M. Martin Jimenez, E. Lim, M. Chavez Mac Gregor, A. Bardia, J. Wu, Q. Zhang, Z. Nowecki, F. Cruz, R. Safin, S-B. Kim, C. Schem, A. Montero, S. Khan, R. Bandyopadhyay, M. Shivhare, M. Patre, J. Martinalbo, L. Roncoroni, P.D. Pérez-Moreno, J. Sohn
Journal: Annals of Oncology (2022)
CN30 Three stage capacity: Consent process for systemic anti-cancer therapy
Authors: F.E. Barrett, O.M. Fitzpatrick, T. Doyle, W.M. Grogan, D.J. McMahon, N. Cooley, A.G. Murphy, M. Conroy, L. Judge, J. Naidoo, R.A. Mclaughlin, C. Matassa, P.G. Morris, B.T. Hennessy, M. Breathnach, K. Egan, D. O'Doherty, O.S. Breathnach
Journal: Annals of Oncology (2022)
111P Interim biomarker analysis of a phase Ib/II study of anti-TIGIT etigilimab (MPH313) and nivolumab in subjects with select locally advanced or metastatic solid tumors (ACTIVATE)
Authors: G. Sarikonda, B.K. Wallace, C. Wiesner, S. Krishnan, J.A. Lewicki, A.M. Kapoun
Journal: Annals of Oncology (2022)
1031P Tislelizumab (TIS) versus docetaxel (TAX) as second- or third-line therapy in previously treated patients (pts) with locally advanced non-small cell lung cancer (NSCLC): Asian versus non-Asian subgroup analysis of the RATIONALE-303 study
Authors: C. Zhou, D. Huang, Y. Fan, X. Yu, Y. Liu, Y. Shu, Z. Ma, Z. Wang, Y. Cheng, J. Wang, S. Hu, E. Poddubskaya, U. Disel, A. Akopov, M. Dvorkin, Y. Wang, S. Ghassemifar, S. Li, G. Rivalland
Journal: Annals of Oncology (2022)
202TiP SOLTI-1805 TOT-HER3 trial: A window-of-opportunity trial of patritumab deruxtecan (HER3-DXd) in patients with treatment-naïve, early breast cancer
Authors: M. Oliveira, J.M. Cejalvo Andujar, M. Margeli Vila, P. Tolosa Ortega, O. Martinez Saez, F.J. Salvador Bofill, J. Cruz Jurado, A.M. Luna Barrera, M.A. Arumi de Dios, M.J. Vidal Losada, J.A. Guerra, S. Pernas Simon, G. Villacampa Javierre, B. Gonzalez-farre, E. Sanfeliu Torres, A. Santhanagopal, C. Falato, J.M. Ferrero Cafiero, T. Pascual, A. Prat
Journal: Annals of Oncology (2022)
477P MTL-STING increases STING expression and potentiates efficacy of checkpoint inhibitor in murine preclinical model
Authors: C.P. Tan, B.M. Ryan, V. Gomez, R. Hodgson, L. Sinigaglia, G. Pizza, K.S. Stathaki, S. Hegre, R. Habib, J. Rossi, N. Habib
Journal: Annals of Oncology (2022)
394P Impact of gender on demographics, resectability, resections, systemic treatment, adverse events and outcomes in metastatic colorectal cancer (mCRC) patients (RAXO-study)
Authors: P.J. Osterlund, T. Salminen, K.I. Lehtomaki, E.J.T. Österlund, A. Uutela, P. Halonen, L-M. Soveri, H.P. Stedt, A-M. Lamminmaki, S.N.B. Aho, T. Muhonen, A. Algars, R. Kallio, E. Heervä, A. Nordin, L.J. Aroviita, P. Nyandoto, J. Kononen, R. Ristamäki, H. Isoniemi
Journal: Annals of Oncology (2022)
356P Biallelic MUTYH germline inactivation in patients with colon polyposis and subjects with sporadic colorectal cancer
Authors: E. Imyanitov, A. Martianov, S. Chuinyshena, Y. Gorgul, E.S. Kuligina, T. Laidus, E. Suspitsin, A. Togo, G. Yanus
Journal: Annals of Oncology (2022)
579P A multicenter evaluation of a low pass whole genome sequencing-based solution for homologous recombination deficiency detection
Authors: A. Buisson, P. Saintigny, E. Pujade-Lauraine, C. Montoto Grillot, D. Varcica, M. Barberis, N. Colombo, A. Harlé, P. Gilson, C. Roma, F. Bergantino, P. Harter, S. Pignata, A.J. Gonzalez Martin, C. Schauer, K. Fujiwara, I.B. Vergote, T.J. Juhler-Nottrup, P-A. Just, I.L. Ray-Coquard
Journal: Annals of Oncology (2022)
252P Real-world progression-free survival (rwPFS) and time to next line of therapy (TTNT) as intermediate endpoints for survival in metastatic breast cancer: A real-world experience
Authors: C. Labaki, Z. Bakouny, T. Sanglier, A. Schmidt, J. Shim, D.A. Braun, F. Bouquet, M. Joyce, W. Xie, S.M. Tolaney, T.K. Choueiri
Journal: Annals of Oncology (2022)
CN65 Feasibility, acceptability and utility of a pilot nurse-led survivorship program for people with metastatic melanoma
Authors: J.E. Lai-Kwon, B. Kelly, S. Lane, R. Biviano, I. Bartula, F. Brennan, I. Kivikoski, H. Dhillon, J. Thompson, A.M. Menzies, G.V. Long
Journal: Annals of Oncology (2022)
371P A phase Ia/b, open-label, multicentre study of the TRAILR2 agonist BI 905711 in patients (pts) with advanced gastrointestinal (GI) cancers
Authors: J.J. Harding, R.D. Hofheinz, M.E. Elez Fernandez, Y. Kuboki, D. Rasco, M. Cecchini, L. Shen, S. Archuadze, J. Geng, F. Haderk, S. Pant
Journal: Annals of Oncology (2022)
242P Investigating the risk of drug-induced interstitial lung disease in patients with metastatic breast cancer treated with antiHER2 regimens through a network meta-analysis approach
Authors: L. Palmero, M.A. Siciliano, P. Di Nardo, D. Basile, L. Cucciniello, B. Pastò, C. Lisanti, A. Membrino, C. Noto, S. Spazzapan, L. Gerratana, F. Puglisi
Journal: Annals of Oncology (2022)
322P Genomic landscape of early-onset sporadic colorectal cancer
Authors: A.N. Holowatyj, S. Hardikar, D. Nix, B. Haaland, M. Larson, E.M. Siegel, J. Carpten, H. Hampel, T. Kennedy, C. Lieu, M.J. Reilley, R. Pearlman, M. Lewis, M. Churchman, H. Colman, C. Ulrich
Journal: Annals of Oncology (2022)
734MO Deep sequencing of the T-cell receptor reveals common and reproducible CD8 T-cell receptor signatures of response to checkpoint immunotherapy
Authors: R.A. Watson, C.A. Taylor, O. Tong, R. Cooper, I. Nassiri, E. Jungkurth, P.K. Sharma, A. Verge de los Aires, E. Ieremia, M.R. Middleton, B.P. Fairfax
Journal: Annals of Oncology (2022)
1028P BIOLUMA: A phase II trial of nivolumab in combination with ipilimumab to evaluate efficacy and safety in lung cancer and to evaluate biomarkers predictive for response – results from the NSCLC cohort
Authors: R.N. Fischer, J. George, A. Scheel, H. Schloesser, P. Brossart, W. Engel-Riedel, F. Griesinger, C. Grohé, J.K. Kern, J. Panse, M. Sebastian, M. Serke, R. Wiewrodt, S. Michels, L. Nogova, R. Riedel, J-P. Weber, R. Büttner, R. Thomas, J. Wolf
Journal: Annals of Oncology (2022)
376P Impact of anti-EGFR therapies on HER2-positive metastatic colorectal cancer (HER2+ mCRC): A systematic literature review and meta-analysis of clinical outcomes
Authors: T. Bekaii-Saab, K. Lach, L-I. Hsu, M.F. Siadak, M. Stecher, J. Ward, R. Beckerman, J.H. Strickler
Journal: Annals of Oncology (2022)
574P Myriad MyChoice plus intermediate performance to discriminate platinum-resistant high-grade ovarian cancer patients
Authors: F. Blanc-Durand, S. Cotteret, C. Genestie, E. Rouleau, J. Michels, E. Colomba, M. Kfoury, P. Pautier, A. Leary
Journal: Annals of Oncology (2022)
969TiP Randomized, phase III study of MK-7684A plus concurrent chemoradiotherapy (cCRT) followed by MK-7684A vs cCRT followed by durvalumab for unresectable, locally advanced, stage III non-small cell lung cancer (NSCLC): KEYVIBE-006
Authors: S. Jabbour, B. Lu, X. Fu, T. Goksel, S. Sugawara, A. Song, S. Quinn, P. Yang, M. Reck
Journal: Annals of Oncology (2022)
901P Cisplatin vs carboplatin in extrapulmonary neuroendocrine carcinoma
Authors: N. McLaughlin, P. McGarrah, R. Eiring, K. Leventakos, M.B. Sonbol, J.S. Starr, T.J. Hobday, T.R. Halfdanarson
Journal: Annals of Oncology (2022)
494TiP Phase Ib study of elimusertib (ATRi; BAY 1895344) in combination with niraparib (PARPi) in patients with advanced solid tumors
Authors: T.A. Yap, P. Konstantinopoulos, R.N. Grisham, D. Gupta, G. Wilkinson, A. Cao, M. Jeffers, N. Sharma
Journal: Annals of Oncology (2022)
93P An AI-driven computational biomarker from H&amp;E slides recovers cases with low levels of HER2 from immunohistochemically HER2-negative breast cancers
Authors: A. Marra, M. Goldfinger, E. Millar, M. Hanna, B. Rothrock, M. Lee, Y. Wang, A. van Eck, L. Trlifaj Tydlitatova, J. Sue, H. Wen, J. Stefanelli, J. Retamero, P. Hamilton, T. Fuchs, D. Klimstra, S. Chandarlapaty, J.S. Reis-Filho
Journal: Annals of Oncology (2022)
526MO Pathological assessment of sentinel lymph node in early-stage cervical cancer: Results from the prospective SENTIX trial (CEEGOG-CX01; ENGOT-CX2)
Authors: D. Cibula, C. Köhler, S. Bajsová, S. Sebestova, I. Zapardiel, G. Di Martino, L.R. van Lonkhuijzen, B. Sehnal, O. Arencibia Sánchez, B. Gil Ibañez, F. Martinelli, J. Presl, L. Minář, R. Marek, P. Kascak, P. Havelka, M. Michal, T. Van Gorp, K. Nemejcova, R. Kocian
Journal: Annals of Oncology (2022)
363P Prevalence of acquired (acq) genomic alterations (GAs) after progression on anti-EGFR mAb (EGFRi) based therapy in metastatic colorectal cancer (mCRC): A systematic review and meta-analysis
Authors: K. Raghav, R. Sun, J. Willis, V. Morris, M. Eluri, N.A. Dasari, Y. Yuan, S. Kopetz, C. Parseghian
Journal: Annals of Oncology (2022)
465P Larotracking: Real-life study of locally advanced/metastatic solid tumor treated with larotrectinib in French expanded access program
Authors: A. Dufresne, O. Huillard, C. Dalban, M. Geier, J. Wassermann, S. Zanetta, M. Cabourg, B. Catargi, C. El Kouri, I. Hrab, M. Laramas, A. Moreira, E.B. Saada, C. Tournigand, T. Valentin, E. Vauleon, R. Mayet, D. Perol, J-Y. Blay
Journal: Annals of Oncology (2022)
930MO PD-L1 expression and outcomes of pembrolizumab and placebo in completely resected stage IB-IIIA NSCLC: Subgroup analysis of PEARLS/KEYNOTE-091
Authors: S. Peters, B. Besse, S. Marreaud, U. Dafni, K. Oselin, L. Havel, E. Esteban Gonzalez, D. Isla, A. Martinez-Marti, M. Faehling, M. Tsuboi, J-S. Lee, K. Nakagawa, J. Yang, S.M. Keller, M.E. Mauer, N. Jha, R.A. Stahel, L. Paz-Ares, M.E.R. O'Brien
Journal: Annals of Oncology (2022)
515P Prognostic significance of elevated serum tumor markers (STM) after the first cycle of chemotherapy in patients with intermediate and poor risk non seminomatous testicular germ cell tumors (NSGCT)
Authors: A. Batra, B. Nayak, P. Singh, R.K. Sahoo, H. Kunhiparambath, S. Kaushal, A. Seth, A.N. Varshney, A. Raj
Journal: Annals of Oncology (2022)
478P Metronomic oral vinorelbine (MOV) combined with tremelimumab (T) + durvalumab (D): Results of the tumor mutational burden-high (TMB-h) and/or microsatellite instability-high (MSI-h) cohort of the MOVIE study
Authors: A. Hervieu, J. Guigay, E. Borcoman, P. Lavaud, E. Coquan, J-S. Frenel, T. De La Motte Rouge, P. Augereau, C. Cropet, F. Legrand, A. Goncalves
Journal: Annals of Oncology (2022)
620O CART-ddBCMA for multiple myeloma: Interim results from phase I study
Authors: M. Frigault, J. Rosenblatt, N. Raje, D. Cook, M. Gaballa, E. Emmanuel-Alejandro, C. Cornwell, K. Banerjee, A. Rotte, C. Heery, D. Avigan, A. Jakubowiak, M. Bishop
Journal: Annals of Oncology (2022)
946P Non-examination of lymph nodes (LN) in early-stage non-small cell lung cancer (eNSCLC) is associated with wedge resections and underutilization of adjuvant (adv) chemotherapy
Authors: J.M. Lee, C.S. Meyer, T.M. To, C-W. Lin, S. Wang, M. Kent, A. Johnson, J.S. Lee
Journal: Annals of Oncology (2022)
312TiP Impact of early palliative care integration on quality of life and symptom burden in patients with high-grade glioma
Authors: J.S. Reis, I.C. Nogueira Costa, C.L.B. Caeiro, A.S.A. Costa, A.C. Fernandes, E. Gonçalves, T. Tavares, C. Moreira, M. Barbosa, A.C. Valente, M.J. Costa
Journal: Annals of Oncology (2022)
1064P Genomic characterization of first line advanced or metastatic non-small cell lung cancer (aNSCLC) patients (pts) subgroups associated with good/bad prognosis
Authors: M. Provencio Pulla, D. Perez Parente, B. Campos Balea, D. Rodriguez Abreu, H. Hasan, S. Olson, N. Pal, S. Wilkinson, F. De Oro Pulido, P. Ruiz Gracia, M. Cobo Dols
Journal: Annals of Oncology (2022)
679P Clinical outcomes in patients with recurrent or metastatic head and neck squamous cell carcinoma after failure of platinum and nivolumab: A multicenter retrospective study
Authors: H. Oka, K. Nagashima, H. Nishi, Y. Kumai, H. Iijima, K. Okami, Y. Shimizu, S. Kano, K. Ito, T. Yamazaki, H. Takahashi, N. Oridate, T. Yokota, T. Koyama, N. Kiyota, K. Kato, S. Kadowaki, Y. Honma
Journal: Annals of Oncology (2022)